首页> 外文期刊>Journal of Molecular Biology >The structure of DNA-bound human topoisomerase II alpha: Conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage
【24h】

The structure of DNA-bound human topoisomerase II alpha: Conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage

机译:DNA绑定的人类拓扑异构酶IIα的结构:协调亚基间相互作用与DNA切割的构象机制。

获取原文
获取原文并翻译 | 示例
           

摘要

Type II topoisomerases are required for the management of DNA superhelicity and chromosome segregation, and serve as frontline targets for a variety of small-molecule therapeutics. To better understand how these enzymes act in both contexts, we determined the 2.9-?-resolution structure of the DNA cleavage core of human topoisomerase IIα (TOP2A) bound to a doubly nicked, 30-bp duplex oligonucleotide. In accord with prior biochemical and structural studies, TOP2A significantly bends its DNA substrate using a bipartite, nucleolytic center formed at an N-terminal dimerization interface of the cleavage core. However, the protein also adopts a global conformation in which the second of its two inter-protomer contact points, one at the C-terminus, has separated. This finding, together with comparative structural analyses, reveals that the principal site of DNA engagement undergoes highly quantized conformational transitions between distinct binding, cleavage, and drug-inhibited states that correlate with the control of subunit-subunit interactions. Additional consideration of our TOP2A model in light of an etoposide-inhibited complex of human topoisomerase IIβ (TOP2B) suggests possible modification points for developing paralog-specific inhibitors to overcome the tendency of topoisomerase II-targeting chemotherapeutics to generate secondary malignancies.
机译:II型拓扑异构酶是处理DNA超螺旋性和染色体分离所必需的,并且是各种小分子治疗剂的一线靶标。为了更好地了解这些酶在这两种情况下的作用,我们确定了与双切口的30 bp双链寡核苷酸结合的人拓扑异构酶IIα(TOP2A)的DNA切割核心的2.9-α分辨率结构。与先前的生物化学和结构研究一致,TOP2A使用在裂解核心的N端二聚化界面形成的二聚核解中心显着弯曲了其DNA底物。但是,该蛋白质还采用了整体构象,其中两个Protomer接触点中的第二个(在C末端)已经分开。这一发现与比较的结构分析一起,揭示了DNA参与的主要位点在与结合亚基-亚基相互作用的控制相关的独特结合,裂解和药物抑制状态之间经历了高度定量的构象转变。鉴于依托泊苷抑制人拓扑异构酶IIβ的复合物(TOP2B),我们对TOP2A模型的进一步考虑表明,开发对系同源物特异性抑制剂以克服靶向拓扑异构酶II的化学疗法产生继发性恶性肿瘤的趋势的可能修饰点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号